A detailed history of Kooman & Associates transactions in Eli Lilly & CO stock. As of the latest transaction made, Kooman & Associates holds 386 shares of LLY stock, worth $352,321. This represents 0.14% of its overall portfolio holdings.

Number of Shares
386
Previous 404 4.46%
Holding current value
$352,321
Previous $314 Million 11.19%
% of portfolio
0.14%
Previous 0.13%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$724.87 - $909.04 $13,047 - $16,362
-18 Reduced 4.46%
386 $349 Million
Q1 2024

May 14, 2024

BUY
$592.2 - $792.28 $5,922 - $7,922
10 Added 2.54%
404 $314 Million
Q4 2023

Jan 29, 2024

SELL
$525.19 - $619.13 $9,453 - $11,144
-18 Reduced 4.37%
394 $230 Million
Q3 2023

Nov 03, 2023

SELL
$434.7 - $599.3 $15,214 - $20,975
-35 Reduced 7.83%
412 $221 Million
Q2 2023

Jul 20, 2023

BUY
$350.74 - $468.98 $156,780 - $209,634
447 New
447 $210 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $867B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Kooman & Associates Portfolio

Follow Kooman & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kooman & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Kooman & Associates with notifications on news.